NextCure, Inc. - NXTC STOCK NEWS

NextCure (Nasdaq: NXTC), a clinical-stage biopharmaceutical company, announced its presentation at the 22nd Annual Needham Virtual Healthcare Conference on April 19, 2023, at 10:15 am ET. The event will include a live audio webcast accessible through the company's website, with a replay available for 30 days afterward. NextCure focuses on developing novel immunomedicines for cancer and immune-related diseases using its proprietary FIND-IO™ platform. The company aims to address unmet medical needs for patients unresponsive to existing therapies. This announcement comes amidst discussions about the company's growth strategies and future prospects in the biopharmaceutical market.

NextCure, Inc. (NXTC) has provided a business update and reported its full-year financial results for 2022. The company is focused on three clinical programs, with clinical data updates expected in 2023. Notably, NC525 (LAIR-1 mAb) has dosed its first patient in a Phase 1 trial for acute myeloid leukemia (AML). As of December 31, 2022, NextCure ended the year with approximately $160 million in cash, which is projected to fund operations into mid-2025. However, the company reported a net loss of $74.7 million for 2022, an increase from a $69.4 million loss in 2021, driven by rising research and development costs.

BELTSVILLE, Md., Feb. 7, 2023 (GLOBE NEWSWIRE) -- NextCure (Nasdaq: NXTC), a clinical-stage biopharmaceutical company, announced its presentation at the SVB Securities Global Biopharma Conference on February 15 at 1:40 pm ET. Investors can access a live audio webcast via the company's website, with a replay available for 30 days post-event.

NextCure focuses on developing novel immunomedicines for cancer and immune-related diseases using its proprietary FIND-IO™ platform. The company aims to provide new treatment options for patients who do not respond to existing therapies.

NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company, announced participation in several upcoming investor conferences. The events include the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 3:30 pm ET, the JMP Securities Hematology and Oncology Summit (virtual) on December 6, 2022, at 10:00 am ET, and the Bank of America Securities 2022 Biotech SMID Cap Conference (virtual) on December 8, 2022, at 3:20 pm ET. Webcasts will be available on the company's website, with replays archived for 30 days.

NextCure (NXTC) has announced a collaboration with LegoChem Biosciences (LCB) to co-develop a B7-H4 antibody drug conjugate (ADC) using LCB's ConjuAll^TM technology. Both companies will share development costs and profits from any commercialized products. The partnership aims to advance the B7-H4 ADC into clinical trials and explore additional ADC targets. This collaboration is positioned as a significant step in addressing unmet cancer treatment needs, as emphasized by both companies' leadership.

NextCure, a clinical-stage biopharmaceutical company, announced the presentation of initial clinical data from its Phase 1 trial of NC762 at the Society for Immunotherapy of Cancer annual meeting. The trial involved 18 patients with advanced solid tumors and demonstrated safety with no dose-limiting toxicities, suggesting potential immune activation. Additionally, details of a Phase 1b/2 trial for NC410, a combination with pembrolizumab, were shared, targeting 100 patients. NextCure aims to enroll patients with various cancers, with reports on initial data expected in mid-2023.

NextCure, Inc. (Nasdaq: NXTC) has announced the discontinuation of its NC318 program after finding no responses in the trial's amended Phase 2 segment. The company will shift focus to its NC410, NC525, and NC762 programs, including an ongoing combination trial of NC410 with pembrolizumab and a Phase 1 trial of NC525 starting in early 2023. These strategic adjustments are anticipated to extend the company’s cash runway into mid-2025.

As of September 30, 2022, NextCure reported cash equivalents of $169.2 million, down from $219.6 million as of December 31, 2021, resulting in a net loss of $18.9 million for the quarter.